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Background/Purpose: Macrophage activation assisted by interferon-gamma (IFN-γ) is a primary mecha-
nism by which Mycobacterium tuberculosis is killed, but IFN-γ production is inhibited in tuberculosis (TB)
patients. The production of IFN-γ is influenced by many factors, such as interleukin (IL)-10, IL-12, IL-18,
and clinical diseases; but the relative importance of each factor is unclear.
Methods: We evaluated the effects of these factors in 46 healthy individuals, 81 patients with TB, and 
88 patients with non-TB pneumonia. The responses of IFN-γ, IL-10, IL-12 and IL-18 were determined from
phytohemagglutinin-stimulated peripheral blood mononuclear cells (PBMCs).
Results: General linear model analysis showed that disease status and IL-12 response were the independ-
ent factors associated with the IFN-γ response. The production of IFN-γ was not affected by IL-10 and 
IL-18. There was a significant relationship between the IFN-γ response and the IL-12 response among 
patients with non-TB pneumonia, patients with TB, and healthy participants (Pearson’s correlation coeffi-
cients of 0.466, 0.483, and 0.464, respectively).
Conclusion: Production of IFN-γ in PBMCs was associated with active pulmonary TB and IL-12 response.
Key Words: interferon-gamma, interleukin-10, interleukin-12, interleukin-18, tuberculosis
Over the past decade, the incidence of tuberculosis
(TB) has been increasing worldwide. It is particu-
larly important to understand the regulation of the
human immune response in TB, because of its po-
tential implication for immune therapy. An ef-
fective immune response against Mycobacterium
tuberculosis infection is important because, without
it, damage to pulmonary tissue and limitation of
airflow may occur. Macrophage activation assisted
by combined cytokines, such as interferon-gamma
(IFN-γ), is a major mechanism by which M tuber-
culosis is killed during the immune response.1
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However, production of IFN-γ is inhibited in TB
patients2,3 via a mechanism that has not been
clearly elucidated.
Many cytokines regulate IFN-γ production.
Swain’s study showed that the presence of inter-
leukin (IL)-4 during the response of naive T helper
(Th) cells causes precursors to develop into a pop-
ulation comprising largely “Th2-like” effectors that
secrete IL-4 and IL-5, but little IL-2 or IFN-γ.4
However, IL-4 expression was significantly de-
creased in TB patients compared with controls.5,6
This suggested that the decreased IL-4 expression
in TB patients could not enhance IFN-γ produc-
tion. Fiorentino’s work revealed that IL-10 could
inhibit the production of IL-2, IL-3, IFN-γ, and
granulocyte-macrophage CSF (GM-CSF) by Th1
cells responding to antigen and antigen present-
ing cells, but Th2 cytokine synthesis was not sig-
nificantly affected.7 Also, IL-12 stimulated T cells
to produce IFN-γ8 and promoted in vitro differ-
entiation of human T cells that secrete IFN-γ.9
Moreover, IL-18 is a cytokine that is a potent in-
ducer of IFN-γ production and plays an important
part in Th1 responses.10 To sum up, decreased
IFN-γ production might be correlated with IL-10,
IL-12, and IL-18 production. However, Lee et al
found that IFN-γ production was not correlated
with IL-10, IL-12, and IL-18 in 18 TB patients and
19 healthy individuals.11 A large scale study is
needed to resolve these discrepancies.
The status of certain other diseases can also in-
fluence production of IFN-γ. For example, chronic
obstructive pulmonary disease (COPD), is asso-
ciated with an active Th1-cell inflammatory process
involving IFN-γ production.12,13 The IFN-γ pro-
duction in peripheral blood mononuclear cells
(PBMCs) from patients with diabetes mellitus
(DM) was decreased compared with that from in-
dividuals without DM14 and impaired IFN-γ pro-
duction from the PBMCs of patients with cancer
has been reported.15,16 Among TB patients, IFN-γ
production was reported to be lower in those with
cavitation in their chest radiograph (CxR) com-
pared with patients without cavitation.17
Here, we report the results of our investiga-
tion into the roles and interactions of possible
regulators of IFN-γ production among patients
with pulmonary TB, those with non-TB pneumo-
nia, and healthy individuals.
Materials and Methods
Participants
Between January 2006 and September 2007, we
recruited 169 patients who had been admitted to
Chang Gung Memorial Hospital, Keelung, Taiwan,
ROC, with possible pulmonary tuberculosis. The
etiological assessment included sputum culture
for common bacteria, Acid-fast bacilli (AFB) test-
ing of a sputum smear, and sputum culture for 
M tuberculosis according to a standard diagnostic
algorithm. Patients treated for > 5 days with an-
tibiotics or anti-TB chemotherapy were excluded.
Ultimately, diagnoses of pulmonary TB were made
in 81 patients and confirmed by positive cultures
for M tuberculosis after 6 weeks. Diagnoses of non-
TB pneumonia were made in 88 patients on the
basis of negative AFB results in sputum, negative
culture results for M tuberculosis, and substantial
resolution of chest radiographs after 1–2 weeks
of follow-up. For comparison, 46 healthy indi-
viduals were enrolled from our staff and persons
visiting our healthy-patient examination center
with normal CxR. All participants provided in-
formed consent, and the study was approved by
our institutional review board.
Interpretations of cavitation on CxR were made
by consensus between two pulmonary physicians.
Cavitation is defined as abnormal pulmonary pa-
renchymal space, not containing lung but filled
with air and/or fluid. The participants’ clinical char-
acteristics were recorded regardless of presence of
COPD, pneumoconiosis, liver cirrhosis, chronic
kidney disease, DM, hypertension, and malignancy.
Pneumonia was defined as the presence of a new
infiltrate on CxR combined with fever or respira-
tory symptoms, such as, coughing, dyspnea, and
sputum production. COPD was diagnosed accord-
ing to guidelines.18 Pneumoconiosis was defined
as the appearance of small rounded opacities on
CxR combined with a history of working with coal.
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Isolation of PBMCs and cell culture
A 10-mL sample of whole blood was obtained
from each participant at 8:00 AM and immediately
mixed with heparin. The PBMCs were isolated by
differential centrifugation over a density gradient
(Ficoll-Plaque; Amersham Biosciences, Uppsala,
Sweden) within 2 hours of collection. A total of
5 × 105 PBMCs were plated in flat-bottomed, 24-
well plates (Nunclon, Aarhus, Denmark) in 1mL of
sterile tissue-culture medium (RPMI 1640; Gibco,
Grand Island, NY, USA) containing 10% heat-
inactivated bovine serum, 1 mM of L-glutamine
(Gibco, Grand Island, NY, USA) and 1 mM of 
sodium pyruvate (Gibco, Grand Island, NY, USA).
Cultures were stimulated with final concentrations
of 0 μg/mL and 5 μg/mL phytohemagglutinin
(PHA; Sigma, St Louis, MO, USA). The plates
were incubated at 37°C in 5% CO2 for 68 hours.
The supernatants were collected from the wells
and stored at −80°C.
Measurement of cytokine responses
Concentrations of IFN-γ, IL-10, and IL-12 in the
supernatants were measured by using human 
enzyme-linked immunosorbent assay (ELISA) kits
(Pierce Biotechnology, Rockford, IL, USA) accord-
ing to the manufacturer’s instructions. Concentra-
tions of IL-18 in the supernatants were measured
using a human ELISA kit (MBL, Woburn, MA,
USA) according to the manufacturer’s instruction.
Cytokine responses were defined as the differences
between levels with and without stimulation.
Statistical analysis
Statistical analysis was performed using SPSS ver-
sion 11.0.1 (SPSS Inc., Chicago, IL, USA). Cytokine
responses and patients’ ages are shown as the
mean ± standard deviation. One-way analysis of
variance with post hoc comparison by Bonferroni
test was used to compare differences in age and
cytokine responses among healthy individuals, pa-
tients with non-TB pneumonia, and patients with
TB. The χ2 test was used to compare the difference
between two categorical variables. The Pearson’s
correlation coefficient (r) was obtained between
two continuous variables. A univariate general
linear model was used to identify independent
predictors of the IFN-γ response. Cavitation in
CxR, sex, patient disease status, and clinical history
served as the fixed factors. Age and cytokine re-
sponses served as the covariates. A p value of <0.05
indicated a statistically significant difference.
Results
The clinical characteristics and cytokine responses
among the 46 healthy individuals, 88 patients
with non-TB pneumonia, and 81 patients with TB
are shown in Table 1. The patients with non-TB
pneumonia and TB were older than the healthy
individuals. The highest percentage of cavitation
was seen on the CxR of patients with TB, followed
by those with non-TB pneumonia and healthy in-
dividuals. The percentage of COPD was highest
in patients with non-TB pneumonia, followed by
those with TB and healthy individuals. The per-
centage of pneumoconiosis, DM, or malignancy
in patients with TB was higher than in healthy
individuals.
Cytokine response among TB patients, 
non-TB pneumonic patients and 
healthy controls
The IFN-γ response in patients with TB was signifi-
cantly lower than that in healthy individuals and
patients with non-TB pneumonia (Table 1). There
were no differences in the IL-10, IL-12, and IL-18
responses among any of the groups of participants.
Association of IFN-g response with co-factors
Table 2 shows the correlation of the IFN-γ response
with age, other cytokine responses, and the pres-
ence or absence of clinical characteristics. General
linear model analysis showed that presence or ab-
sence of TB and non-TB pneumonia and the IL-12
response were the independent factors associated
with IFN-γ response. There were no relationships
between the IFN-γ response and age, IL-10 re-
sponse, or IL-18 response. There was a significant
relationship between the IFN-γ response and the
IL-12 response among patients with non-TB
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pneumonia, patients with TB, and healthy indi-
viduals (Pearson’s correlation coefficients of 0.466,
0.483, and 0.464, respectively; Figure).
Discussion
IL-12, which is secreted from activated macro-
phages/monocytes, dendritic cells, and neutrophils,
enhances the differentiation of native T cells to
Th1 cells, which secrete IFN-γ. After stimulation
by M tuberculosis antigen, IFN-γ production from
PBMCs was correlated with IL-12 p40 production
in TB patients.19 The defect in IFN-γ secretion
could be overcome by culture with IL-12.20 Thus,
it is reasonable to conclude that IFN-γ production
is correlated with the IL-12 response. However,
Lee et al found that the IFN-γ response from puri-
fied protein derivatives (PPD)-stimulated PBMCs
was not correlated with the IL-12 response in pa-
tients with TB.11 The major difference between
Lee’s study and our work is the stimulator. The
PPD was used in Lee’s study and PHA was used
in this work. The reason for using PHA instead of
PPD was that the response to PHA presented gen-
eral cell-mediated immunity rather than the re-
sponse to TB. Different stimulators might result
in different results. The number of patients and
power of analysis in our study are greater than
those in the study by Lee et al, yet there was no
significant difference in IL-12 production among
the three groups in our study either. The reason
is the B value. The B value is the estimate of the
change in the dependent variable that can be at-
tributed to a change of one unit in the independ-
ent variable. The B values of the groups are larger
than that of the IL-12 response. The effect of the
groups on IFN-γ response was more than that of
the IL-12 response.
Another independent factor influencing IFN-γ
production was the patients’ disease status. It is
well known that patients with pulmonary TB have
a poor IFN-γ response. Even though IL-12 was
correlated with the IFN-γ response, M tuberculosis
infection was still an independent factor predict-
ing poor response to IFN-γ. We can reasonably
Table 1. Clinical characteristics and cytokine responses among healthy individuals, patients with 
non-tuberculosis pneumonia, and patients with tuberculosisa
Healthy (n = 46) Pneumonia (n = 88) Tuberculosis (n = 81)
Age (yr) 51.8 ± 19.7 65.3 ± 17.9b 61.7 ± 19.7b
Male 32 (69.6) 64 (72.7) 59 (72.8)
Cavitation in CxR 0 17 (19.3)b 37 (45.7)b,c
History
COPD 2 (4.3) 31 (35.2)b 15 (18.5)b,c
Pneumoconiosis 1 (2.2) 7 (8.0) 13 (16.0)b
Liver cirrhosis 0 (0) 5 (5.7) 4 (4.9)
CKD 2 (4.3) 2 (2.3) 4 (4.9)
Diabetes mellitus 4 (8.7) 19 (21.6) 25 (30.9)b
Hypertension 8 (17.4) 23 (26.1) 14 (17.3)
Malignancy 0 (0) 6 (6.8) 7 (8.6)b
Cytokine responses (pg/mL)
IFN-γ 1200.22 ± 623.06 1023.48 ± 755.52 626.31 ± 594.47b,c
IL-10 373.13 ± 264.15 405.83 ± 272.86 453.70 ± 362.08
IL-12 637.69 ± 584.51 709.90 ± 551.68 668.08 ± 553.72
IL-18 5.76 ± 280.31 59.98 ± 300.14 6.48 ± 29.43
aData are presented as mean ± standard deviation or n (%); bp < 0.05 compared with healthy individuals; cp < 0.05 compared with
pneumonia.CxR = chest radiography; COPD = chronic obstructive pulmonary disease; CKD = chronic kidney disease; IFN = interferon;
IL = interleukin.
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hypothesize that either specific antigens or secre-
tory toxins from M tuberculosis might significantly
alter the production of IFN-γ. Further investiga-
tions are needed to identify such specific antigens
or secretory toxins, which might be good targets
for the development of neutralizing antibodies.
Patients with multi-drug resistant M tuberculosis
might especially benefit from such new agents.
Table 2. General linear model analysis for IFN-γ response to identify the independent factors among clinical
characteristics and other cytokine responses
B IFN-γ response or (r)a p
Age 3.313 0.011 0.174
Sex
Male 0b 865.29 ± 709.36
Female 163.602 1031.46 ± 691.85 0.085
Cavitation in CxR
Yes 0b 711.96 ± 678.25
No 23.609 978.64 ± 705.65 0.818
Groups
Healthy 216.380 1200.22 ± 623.06 0.070
Non-TB pneumonia 0b 1023.48 ± 755.52
TB –403.537 626.31 ± 594.47 < 0.001
COPD
Yes 0b 826.44 ± 727.98
No 150.711 936.15 ± 700.99 0.259
Pneumoconiosis
Yes 0b 720.65 ± 790.66
No –91.143 932.34 ± 696.31 0.599
Liver cirrhosis
Yes 0b 1246.12 ± 783.92
No –49.665 897.05 ± 701.77 0.819
Chronic kidney disease
Yes 0b 1050.51 ± 541.69
No –201.491 906.29 ± 712.96 0.355
Diabetes mellitus
Yes 0b 927.94 ± 732.30
No –44.933 906.98 ± 701.57 0.665
Hypertension
Yes 0b 895.55 ± 709.09
No 202.421 915.92 ± 708.31 0.062
Malignancy
Yes 0b 672.10 ± 678.51
No 143.459 927.08 ± 707.49 0.428
IL-10 response 0.220 0.060 0.103
IL-12 response 0.616 0.442 < 0.001
IL-18 response 0.323 0.060 0.068
aData are presented as the mean ± standard deviation (in pg/mL) for categorical variables or the Pearson’s correlation coefficient (r)
value for continuous variables; b0 is set as a reference. B = B value; IFN = interferon; CxR = chest radiography; TB = tuberculosis;
COPD = chronic obstructive pulmonary disease; IL = interleukin.
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This study further demonstrated that the se-
cretion of cytokines IFN-γ, IL-10, IL-12, and IL-18
from PBMCs was similar between healthy indi-
viduals and patients with non-TB pneumonia. 
In acute infection of the lower respiratory tract,
eradication of pathogens is mostly performed by
neutrophils with assistance by cytokines and che-
mokines.21 Neutrophils secrete IL-12 in the lungs,
and IL-12 amplifies IFN-γ to enhance neutrophil-
mediated host defenses during pneumonia.22 Even
in patients with non-TB pneumonia, the responses
of cytokines IFN-γ, IL-10, IL-12, and IL-18 were
unimpaired compared with those in the healthy
individuals in this study. This suggests that IFN-γ,
IL-10, IL-12, and IL-18 might not correlate with
pulmonary infection by pathogens other than 
M tuberculosis.
In this study, the IFN-γ response was not cor-
related with the IL-10 and IL-18 responses, even
in the subgroup analysis of patients with TB (data
not shown). This observation is similar to that of
Lee et al11 Although IL-10 can inhibit differentiation
of Th1 cells, IL-10 could not suppress IFN-γ pro-
duction from PBMCs among healthy individuals,
patients with non-TB pneumonia, and those with
TB. Furthermore, there was no difference in IL-18
gene expression between healthy individuals and
patients with pulmonary TB.23 No significant
correlation between IFN-γ and IL-18 productions
was observed in stimulated PBMCs of patients
with TB.24
The distribution of comorbid diseases and the
association between comorbid diseases and IFN-γ
responses in this study were similar to our previ-
ous studies.3,25 Although COPD is associated with
an inflammatory process involving IFN-γ produc-
tion,12,13 there was no difference in IFN-γ produc-
tion between patients with COPD and without
COPD in this study. Lower respiratory tract infec-
tion might greatly affect the mechanism of IFN-γ
production in patients with COPD. No difference
in IFN-γ response between patients with DM and
without DM was found. This result was consistent
with that in our previous study, which showed
that the IFN-γ production from stimulated PBMCs
of healthy individuals was not significantly altered
after glucose treatment.26 In a longitudinal study
by Tsukaguchi et al, IFN-γ production in TB pa-
tients with well controlled DM or without DM
returned to the control level by 6 months, whereas
IFN-γ production in TB patients with poorly con-
trolled DM remained depressed.27 Thus, the IFN-γ
response might not be associated with DM history,
but rather with the status of blood sugar control.
In this study, the mean IFN-γ response in pa-
tients with malignancy was relatively lower than
those without malignancy, but statistical analysis
did not show significance. The Th1 cytokines, such
as IFN-γ, were reported to be down regulated in
patients with head and neck squamous cell carcino-
mas.28 A lower IFN-γ response from lymphocytes
in patients with lung cancer has been observed
compared with healthy individuals.29 Addition-
ally, patients with advanced cancer had poor nu-
tritional status. All of the above factors favored 
a lower IFN-γ response in patients with malig-
nancy. However, compared with M tuberculosis
infection and IL-12 response, the effect of malig-
nancy was not significant in our study. In TB pa-
tients, IFN-γ response with cavitation on the CxR
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Figure. The scatter-plot shows the relationship between the
interferon (IFN)-γ and interleukin (IL)-12 responses among
healthy individuals (Co), patients with non-tuberculosis
pneumonia (Pn), and patients with tuberculosis (TB). The
regression line is shown for the total population. The
Pearson’s correlation coefficient (r) for the total population
and each group are as follows: total population: r = 0.442,
p < 0.001; Pn (squares): r = 0.466, p < 0.001; TB (solid tri-
angles): r=0.483, p<0.001; Co (stars): r=0.464, p=0.001.
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was significantly lower than those without cavi-
tation (data not shown), which was similar to our
previous study.17 Nevertheless, compared with 
M tuberculosis infection and IL-12 response, we
found low association between IFN-γ response
and cavitation on the CxR. The relationship of 
M tuberculosis infection to IFN-γ response was
higher than that of cavitation on CxR.
There are two limitations in this study. One is
that the subtypes of the participants’ PBMCs were
not analyzed. Naturally occurring CD4+CD25+
regulatory T (Treg) cells are a subset of CD4+
T cells with suppressive and inhibitory effects to-
ward T cells.30 The percentage of Treg cells in the
patients with TB has been shown to be higher than
that in healthy individuals, and Treg cells could
decrease the number of IFN-γ-producing T cells.31
Treg cells also suppressed the IFN-γ response in
PBMCs of patients with active TB.32 Whether the
percentage of Treg cells was an independent fac-
tor affecting IFN-γ production is unknown. An-
other limitation is the influence of latent TB and
previous TB infections. It is possible to have la-
tent TB or previous TB infection in the pneumo-
nia group. But, it is less likely to have latent TB or
previous TB infection in the healthy group be-
cause of the normal CxR. IFN-gamma response
was restored after chemotherapy for 6 months.33
IFN-γ gene expression from PBMCs were similar
between uninfected and latent TB subjects.34 Thus,
we could reasonably hypothesize that the influ-
ence of latent TB or previous TB infections was
minimal in this work.
In conclusion, IFN-γ production in PBMCs was
influenced by active pulmonary TB and also af-
fected by IL-12. The IFN-γ response was not re-
lated to the IL-10 or IL-18 responses, malignancy,
DM, COPD, or cavitation in CxR among healthy
individuals and patients with TB and non-TB
pneumonia. The production of IFN-γ was not sup-
pressed by IL-10 and not induced by IL-18 among
healthy individuals and patients with non-TB
pneumonia or TB. Further studies to search for
specific M tuberculosis antigens and toxins that
inhibit production of IFN-γ are needed and help
identify new agents to control TB.
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